World News
-
Bright Uro expands Glean platform with FDA-cleared abdominal sensor for catheter-free urodynamics
Urodynamics assesses how the bladder, urethra, and sphincters store and release urine to identify causes of leakage or obstruction.
-
Roche to buy PathAI for up to US$1.05B to advance AI-driven digital pathology
The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.
-
GSK bets US$1B on SiranBio’s ALK7 siRNA to disrupt the obesity market
The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.
-
Angelini Pharma to acquire Catalyst Pharmaceuticals in US$4.1B U.S. rare disease expansion
Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.
-
Madrigal expands MASH pipeline with US$1B licensing deal for Arrowhead’s siRNA therapy
Under the agreement, Madrigal will take over the development, manufacturing, and commercialisation of Arrowhead’s investigational therapy, ARO-PNPLA3.
-
Olympus partners with EndoRobotics to expand robot-assisted gastrointestinal procedures
The robot-assisted technologies under this agreement respond directly to this challenge by improving clinical outcomes and reducing procedural complications.
-
Bayer to acquire Perfuse Therapeutics in US$2.45B deal to strengthen its ophthalmology pipeline
The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.
-
Eli Lilly invests US$4.5B more in Indiana manufacturing to increase production capacity
The additional funding will enhance two key facilities within the Lebanon complex, known collectively as the LEAP Research and Innovation District.
-
Sanofi invests US$212M in Toronto’s AI hub to accelerate drug innovation
The project is backed by a conditional grant of up to C$5 million (US$3.6 million) from the Ontario government through the Invest Ontario Fund.
-
Insulet launches EVOLVE trial for fully closed-loop type 2 diabetes system
Insulet received Investigational Device Exemption approval from the U.S. Food and Drug Administration in March 2026, clearing the way for the trial to begin.